07-Jan-2021 9:47 PM
European Commission authorises second safe and effective vaccine against COVID-19
Direct News Source
Today, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Moderna, the second COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.
Read More
This CAPA Analysis Report is 768 words.
You must log in to read the rest of this article.
Got an account? Log In
Create a CAPA Account
Get a taste of our expert analysis and research publications by signing up to CAPA Content Lite for free, or unlock full access with CAPA Membership.
| Inclusions | Content Lite User | CAPA Member |
|---|---|---|
| News | ||
| Non-Premium Analysis | ||
| Premium Analysis | ||
| Data Centre | ||
| Selected Research Publications |
This press release was sourced from European Commission on 06-Jan-2021.